B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening.
about
Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass graftingPro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentEffects of Low-Dose Recombinant Human Brain Natriuretic Peptide on Anterior Myocardial Infarction Complicated by Cardiogenic Shock.Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor.Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbitsLong-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat modelExtracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humansLebetin 2, a Snake Venom-Derived Natriuretic Peptide, Attenuates Acute Myocardial Ischemic Injury through the Modulation of Mitochondrial Permeability Transition Pore at the Time of Reperfusion.Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia.KATP Channels in the Cardiovascular System.Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase CExogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion InjuryRole of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function.Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury.Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study.Impact of nesiritide on renal function and mortality in patients suffering from heart failure.Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/protein kinase G-dependent cardioprotection in ratsPatents related to therapeutic activation of K(ATP) and K(2P) potassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and general anesthetics.Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications.Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development.Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.Natriuretic peptides in cardiometabolic regulation and disease.Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.Brain natriuretic peptide and right heart dysfunction after heart transplantation.Current and future uses of nesiritide.Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Iα.NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.B Type natriuretic peptide: a good omen in myocardial ischaemia?Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation.B-type natriuretic peptide and adiponectin releases in rat model of myocardial damage induced by isoproterenol administration.Ischemia/reperfusion is an independent trigger for increasing myocardial content of mRNA B-type natriuretic peptide.Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study.
P2860
Q24644704-C8F2D49B-DBBB-4093-A0FC-3FAE4F0942A2Q30234356-6E79487C-C300-49D2-8178-CC71623FC5FDQ33573360-1F6BCEE7-FDCA-40EF-A086-30D3A8860DF2Q33615284-226E4EF8-19D2-4F82-8AB8-83EDD67DBB33Q34048466-BD03D197-D90D-4565-8C6D-1E6A681F7CB6Q34219629-2144E9C6-26C4-4526-9875-CEC01A2B3B8DQ34277031-C247509F-F223-402B-840C-01C8846659C6Q34543457-ACB1F26A-60BA-4E92-B1B2-56A287F8C0B1Q34891600-AC2E069B-7546-49C7-909A-452AB055693AQ35286339-C7026598-9107-4750-8896-AB3E9325ED81Q35954229-97FD93AE-46FA-4A94-980E-D8E3331256D5Q36129944-1F3C95DA-4142-4A87-80E5-35FFAC3E7414Q36144664-2AD68107-2813-4DD3-BA9C-9EE8382CCE30Q36236490-914FF3B0-7B47-41DD-BB9E-DA8D977F5845Q36422478-69845CA4-9621-4010-B5C8-C12FC1B44FAFQ36893258-75B4227B-B7F7-4E82-8B50-4E9093745BD7Q37049458-E7065455-4B81-4169-B181-73C3B080AB12Q37240960-C413983A-A431-4318-AE6D-E293353C45C4Q37298343-7BC640B3-83B0-47EA-B0E3-87128914C574Q37329716-DB6E5907-E346-4772-AB17-EFE5B232E25AQ37404597-133063D5-CB8A-4056-A99E-5CF222DC0622Q37481201-F79BC947-B24A-4E36-9984-DF25EF1CD563Q37481320-72C204C1-5602-403B-83F7-FA6BC50D85E5Q37626852-EEC360C3-CB80-4725-8BC8-3EC65256ABF5Q37633999-340A41D0-9CD3-4049-A9AE-3B23B41AD3AFQ37926558-B9798F75-2045-47F0-AB78-B6C97D459498Q38112347-7D700C98-8250-4DBD-A20F-2B7724A33DF7Q38191314-EF66AE38-11FC-4822-9727-533C515435A7Q38211333-FC76904E-9088-4A31-B137-2B84EB54180BQ38247701-AD5A44E2-46B7-4CF4-B042-23C92E75471AQ38258238-A6BFFF14-10F6-4385-813F-BCAFA5DB6BD9Q38897414-3DBB9C56-C6DA-4ACC-85DE-EA1C5331A6E3Q40442907-426AED1E-4957-4D9A-886F-9F9C4DAD1111Q41189484-6812E222-FD41-4F3D-A94A-D675AF41E8CDQ41879996-7AC1575D-E25F-4D0A-B348-6E7D84589193Q43014687-833ADF97-2239-4AD2-8E0E-BCE18B7EDEFFQ43116126-5BD25959-80CB-4BB3-8065-6266C43BD77FQ43154414-F02C9F1B-CF19-4D9F-8214-81956247CC88Q44116990-A1D8016A-E10A-4A8F-A405-BE6F893AA13BQ44429060-D55192D8-3025-4583-9FA2-38158DC4888A
P2860
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@en
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@nl
type
label
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@en
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@nl
prefLabel
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@en
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@nl
P2093
P2860
P1476
B-type natriuretic peptide lim ...... arts via KATP channel opening.
@en
P2093
Annamaria Onody
Claus Martin
Derek M Yellon
Gary F Baxter
Gerd Heusch
Peter Ferdinandy
Rainer Schulz
Savio P D'Souza
P2860
P304
P356
10.1152/AJPHEART.00902.2002
P577
2003-01-09T00:00:00Z